Risedronate reduces fracture risk in children with osteogenesis imperfecta .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Lancet. 2013 Aug 5. pii: S0140-6736(13)61091-0.147 children with osteogenesis imperfecta were randomized to receive risedronate (an oral bisphosphonate) or a placebo in order to evaluate the safety and efficacy of risedronate in this population. The study demonstrated that risedronate was superior in the mean improvement in lumbar spinal BMD- assessed using dual-energy x-ray absorptiometry scanning, and led to a reduced risk of clinical fracture in children. The study concluded that risedronate is a safe and effective treatment measure for children with osteogenesis imperfecta and recommended it as an appropriate option.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
